⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
CRBU — Caribou Biosciences, Inc.
Last scan (Sept. 16, 2026): price $1.27, RSI 28.77, relative volume 1.49x, MACD ⚪ No, score 57.48.
It's trading below its 200-day average, with an RSI of 28.77 in oversold territory — technically weak, though that can also signal the pessimism is already priced in. Neither the MACD nor a range breakout gives a technical entry signal right now. Relative volume of 1.49x is somewhat above normal. The analysts' average target price implies +833.9% upside — one of the score's strongest signals. Today it holds rank #17 in the Penny group on Smart Scanner's upside + relative volume ranking.
Price chart
CRBU
Price: $1.3 · RSI (14): 46.49 · Rel. volume: 4.62x · Breakout: No
- Current price: ($1.3) — solid white line — the latest available closing price.
- Target price: ($11.86) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($1.25) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
CRBU
Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell…
- Buy 7
- Hold 0
- Sell 0
Average target price: $11.86 (+812.1% vs. current price) · range $4.0 – $32.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
Not enough data to calculate it (no recent earnings or data unavailable).
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Not enough data (requires future growth estimates).
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Low leverage: conservative balance sheet, less risk if interest rates rise.
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Doesn't pay dividends: reinvests earnings into growth instead of distributing them.
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
More volatile than the market: higher potential gain, but also higher potential loss.
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.